Browse > Article

Effects of Administration of Oxytocin Antagonist on Implantation and Pregnancy Rates in Patients with Repeated Failure of IVF/ICSI Treatment  

Ahn, Jun-Woo (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Chung-Hoon (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center)
Kim, So-Ra (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center)
Jeon, Gyun-Ho (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Sung-Hoon (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center)
Chae, Hee-Dong (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center)
Kang, Byung-Moon (Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center)
Publication Information
Clinical and Experimental Reproductive Medicine / v.36, no.4, 2009 , pp. 275-281 More about this Journal
Abstract
Objective: This study was performed to evaluate the effect of oxytocin antagonist on the outcome of IVF/ICSI cycles in infertile patients with repeated failure of IVF/ICSI treatment. Method: Forty patients who had experienced two or more failures of IVF/ICSI treatment without low ovarian reserve, were recruited for this prospective randomized study. All patients received controlled ovarian stimulation (COS) using GnRH antagonist multidose protocol (MDP). For the intervention group, intravenous administration of atosiban (mixed vasopressin $V_{1A}$/oxytocin antagonist) started with a bolus dose 6.75 mg one hour before embryo transfer (ET) and continued at an infusion rate of 18 mg/hour. After ET, administered atosiban was reduced to 6 mg/hour and continued for 2 hours. The main efficacy endpoints were clinical pregnancy rate and implantation rate. Results: Patients' characteristics were comparable in the intervention and control groups. COS parameters and IVF results were also similar. The number of uterine contractions for 3 minutes measured just before ET was significantly lower in the intervention group than control group ($3.5{\pm}1.4$ vs $8.7{\pm}2.2$, p<0.001). While there was no statistically significant difference in the clinical pregnancy rate between control group and intervention group (20.0% and 40.0%, p=0.168), the implantation rate was significantly higher in the intervention group, with 16.9% (11/65) compared with 6.0% (4/67) in the control group (p=0.047). There were no differences in ectopic pregnancy rate and miscarriage rate between the two groups. Conclusion: This study demonstrates that administration of oxytocin antagonist during ET can improve the implantation rate probably by decreasing the frequency of uterine contractions in infertile patients undergoing IVF/ICSI treatment.
Keywords
Oxytocin antagonist; In vitro fertilization; Embryo transfer; Implantation rate;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Poindexter AN, 3rd, Thompson DJ, Gibbons WE, Findley WE, Dodson MG, Young RL. Residual embryos in failed embryo transfer. Fertil Steril 1986; 46(2): p. 262-7   PUBMED   ScienceOn
2 Fanchin R, Righini C, de Ziegler D, Olivennes F, Ledee N, Frydman R. Effects of vaginal progesterone administration on uterine contractility at the time of embryo transfer. Fertil Steril 2001; 75(6): p. 1136-40   DOI   ScienceOn
3 Pusey J, Kelly WA, Bradshaw JM, Porter DG. Myometrial activity and the distribution of blastocysts in the uterus of the rat: interference by relaxin. Biol Reprod 1980; 23(2): p. 394-7   DOI   ScienceOn
4 Harper MJ, Bennett JP, Rowson LE. A possible explanation for the failure of non-surgical ovum transfers in the cow. Nature 1961; 190: p. 789-90   DOI   ScienceOn
5 Torre A, Scheffer JB, Schonauer LM, Frydman N, Fanchin R. Mock embryo transfer does not affect uterine contractility. Fertil Steril 2009   DOI   ScienceOn
6 Fanchin R, Righini C, Olivennes F, Taylor S, de Ziegler D, Frydman R. Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization. Hum Reprod 1998; 13(7): p. 1968-74   DOI   ScienceOn
7 Pinheiro OL, Cavagna M, Baruffi RL, Mauri AL, Petersen C, Franco JG, Jr. Administration of beta2-adrenergic agonists during the peri-implantation period does not improve implantation or pregnancy rates in intracytoplasmic sperm injection (ICSI) cycles. J Assist Reprod Genet 2003; 20(12): p.513-6   DOI   PUBMED   ScienceOn
8 Mansour RT, Aboulghar MA, Serour GI, Amin YM. Dummy embryo transfer using methylene blue dye. Hum Reprod 1994; 9(7): p. 1257-9   DOI   PUBMED   ScienceOn
9 Dorn C, Reinsberg J, Schlebusch H, Prietl G, van der Ven H, Krebs D. Serum oxytocin concentration during embryo transfer procedure. Eur J Obstet Gynecol Reprod Biol 1999; 87(1): p. 77-80   DOI   ScienceOn
10 Knutzen V, Stratton CJ, Sher G, McNamee PI, Huang TT, Soto-Albors C. Mock embryo transfer in early luteal phase, the cycle before in vitro fertilization and embryo transfer: a descriptive study. Fertil Steril 1992; 57(1): p. 156-62   DOI   PUBMED   ScienceOn
11 Akerlund M. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea. Prog Brain Res 2002; 139: p. 359-65   DOI   PUBMED
12 Mansour RT, Aboulghar MA. Optimizing the embryo transfer technique. Hum Reprod 2002; 17(5): p. 1149-53   DOI   ScienceOn
13 Moon HS, Park SH, Lee JO, Kim KS, Joo BS. Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer. Fertil Steril 2004; 82(4): p. 816-20   DOI   ScienceOn
14 Pierzynski P, Reinheimer TM, Kuczynski W. Oxytocin antagonists may improve infertility treatment. Fertil Steril 2007; 88(1): p. 213 e19-22   DOI   ScienceOn